The mRNA Vaccines and Therapeutics Market is estimated at $3.43 billion in 2018. The Standardized Therapeutic Cancer mRNA Vaccines segment held a share of 35.47% in 2018 and is projected to grow with a CAGR of 9.77% in next ten years.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 184-page report you will receive 130 charts– all unavailable elsewhere.
The 184-page report provides clear detailed insight into the mRNA Vaccines and Therapeutics Market. Discover the key drivers and challenges affecting the market.
Report Scope
• Revenue and growth forecasts from 2019 to 2029 for the mRNA Vaccines and Therapeutics market
• Revenue and growth forecasts from 2019 to 2029 for the mRNA Vaccines and Therapeutics market by type: • Standardized Therapeutic Cancer mRNA Vaccines • Individualized Therapeutic Cancer mRNA Vaccines • Therapeutic Infectious Disease mRNA Vaccines • mRNA Therapeutic for Other Diseases
• Revenue and growth forecasts from 2019 to 2029 for the mRNA Vaccines and Therapeutics market by Mechanism of Action: • Bioengineered Vaccine • Gene Therapy (Gene Silencing/Suppression) • Gene Transcription (Protein Generation) • Cell Therapy • Monoclonal Antibody • Others
• Revenue and growth forecasts from 2019 to 2029 for the leading regional and national markets: • North America: the revenues are further broken down into the US and Canada • Europe: the revenues are further broken down into the UK, Germany, France, Italy and Spain • Asia-Pacific: the revenues are further broken down into China, Japan and India • Rest of the World: the revenues are further broken down into Brazil, Mexico, Russia and South Africa
• Discussion and profiles of the leading players in the mRNA Vaccines and Therapeutics market: • Argos Therapeutics, Inc. • BioNTech AG • CureVac AG • eTheRNA Immunotherapies • ethris GmbH • In-Cell-Art • Moderna Therapeutics • Sangamo Therapeutics, Inc. • Tiba Biotech • Translate Bio, Inc.
• Qualitative analysis of factors that drive and restrain the mRNA Vaccines and Therapeutics market. Trends analysis of the mRNA Vaccines and Therapeutics market.
• mRNA Vaccines and Therapeutics R&D pipeline analysis
• Key Questions Answered by this Report: • How is the mRNA vaccines and therapeutics market evolving? • What is driving and restraining the mRNA vaccines and therapeutics market? • What are the market shares of the leading segments of the mRNA vaccines and therapeutics market in 2018? • What will be the main driver of the overall market from 2019 to 2029? • How will the market shares of the leading national markets change by 2029 and which country will lead the market in 2029? • How will the industry evolve during the period between 2019 and 2029? • Who are the leading companies in this market?
Visiongain’s study is intended for anyone requiring commercial analyses for the mRNA Vaccines and Therapeutics market. You find data, trends and predictions.
Buy our report today mRNA Vaccines and Therapeutics Market Forecast 2019-2029: Standardized Therapeutic Cancer mRNA Vaccines, Individualized Therapeutic Cancer mRNA Vaccines, Therapeutic Infectious Disease mRNA Vaccines, mRNA Therapeutic for Other Diseases, Bioengineered Vaccine, Gene Transcription, Monoclonal Antibody, Gene Therapy, Cell Therapy.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global mRNA Vaccines and Therapeutics Market Overview 1.2 Global mRNA Vaccines and Therapeutics Market Segmentation 1.3 Overview of Findings 1.4 Structure of the Report 1.5 Why You Should Read This Report 1.6 How This Report Delivers 1.7 Main Questions Answered by this Report 1.8 Who is this Report for? 1.9 Research and Analysis Methods 1.10 Frequently Asked Questions (FAQ) 1.11 Associated Reports 1.12 About Visiongain
2. Introduction to mRNA Vaccines and Therapeutics 2.1 History of mRNA Vaccines & Therapeutics Development 2.2 Incidence and Prevalence of Chronic Diseases and Major Infectious Diseases 2.3 Prevention and Treatment Using mRNA Vaccines & Therapeutics 2.3.1 mRNA Modifications 2.3.2 mRNA Efficiencies 2.3.3 Adjuvant/Stimulant & Carrier Technologies for mRNA-based Vaccines 2.3.4 Carriers for mRNA-based Protein & Antibody Therapeutics
4. Global mRNA Vaccines & Therapeutics: Market Size and Forecast 2019-2029 4.1 mRNA Vaccines and Therapeutics Market Overview, 2018 4.2 The World mRNA Vaccines and Therapeutics Market 4.3 World mRNA Vaccines and Therapeutics Market: Sales Forecast 2019-2029 4.4 Changing Market Shares by Region 2018-2029 5. mRNA Vaccines and Therapeutics Market: Drivers, Restraints, and Trends Analysis 2019-2029 5.1 mRNA Vaccines and Therapeutics Market: Drivers 2019-2029 5.1.1 Rising Adoption of Personalized Medicine for Effective Treatment 5.1.2 Advantages Offered by mRNA-based Products 5.1.3 Rising Funding by Pharmaceutical Companies and Government Organizations 5.2 mRNA Vaccines and Therapeutics Market: Restraints 2019-2029 5.2.1 Delivery of mRNA therapeutics and vaccines 5.2.2 Stringent Government Regulations for mRNA-based Product Approvals 5.3 mRNA Vaccines and Therapeutics Market: Trends 2019-2029 5.3.1 Rising adoption of gene therapy-based products
6. mRNA Vaccines & Therapeutics by Type: Market Size and Forecast 2019-2029 6.1 Market Forecast 2019-2029 6.2 Market Share of mRNA Vaccines and Therapeutics by Type 6.2.1 Standardized Therapeutic Cancer mRNA Vaccines: Market Forecast, 2019-2029 6.2.2 Individualized Therapeutic Cancer mRNA Vaccines: Market Forecast, 2019-2029 6.2.3 Therapeutic Infectious Disease mRNA Vaccines: Market Forecast, 2019-2029 6.2.4 mRNA Therapeutic for Other Diseases: Market Forecast, 2019-2029
7. mRNA Vaccines & Therapeutics by Mechanism of Action: Market Size and Forecast 2019-2029 7.1 Market Forecast 2019-2029 7.2 Market Share of mRNA Vaccines and Therapeutics by Mechanism of Action 7.2.1 Bioengineered Vaccine: Market Forecast, 2019-2029 7.2.2 Gene Therapy (Gene Silencing/Suppression): Market Forecast, 2019-2029 7.2.3 Gene Transcription (Protein Generation): Market Forecast, 2019-2029 7.2.4 Cell Therapy: Market Forecast, 2019-2029 7.2.5 Monoclonal Antibody: Market Forecast, 2019-2029 7.2.6 Others: Market Forecast, 2019-2029 8. mRNA Vaccines & Therapeutics Regional Market: Market Size and Forecast 2019-2029 8.1 Leading National Markets of mRNA Vaccines & Therapeutics 2019-2029 8.2 North America mRNA Vaccines & Therapeutics: Market Size and Forecast 2019-2029 8.2.1 The US mRNA Vaccines and Therapeutics: Market Forecast 2019-2029 8.2.2 Canada mRNA Vaccines and Therapeutics: Market Forecast 2019-2029 8.3 Europe mRNA Vaccines & Therapeutics: Market Size and Forecast 2018-2029 8.3.1 Germany mRNA Vaccines and Therapeutics: Market Forecast 2019-2029 8.3.2 UK mRNA Vaccines and Therapeutics Market: Forecast 2019-2029 8.3.3 French mRNA Vaccines and Therapeutics Market: Forecast 2019-2029 8.3.4 Italian mRNA Vaccines and Therapeutics: Market Forecast 2019-2029 8.3.5 Spanish mRNA Vaccines and Therapeutics: Market Forecast 2019-2029 8.4 Asia-Pacific mRNA Vaccines & Therapeutics Market Size and Forecast 2019-2029 8.4.1 Japanese mRNA Vaccines and Therapeutics: Market Forecast 2019-2029 8.4.2 Chinese mRNA Vaccines and Therapeutics: Market Forecast 2019-2029 8.4.3 Indian mRNA Vaccines and Therapeutics: Market Forecast 2019-2029 8.5 Row mRNA Vaccines & Therapeutics Market Size and Forecast 2018-2029 8.5.1 Brazilian mRNA Vaccines and Therapeutics: Market Forecast 2019-2029 8.5.2 Mexico mRNA Vaccines and Therapeutics: Market Forecast 2019-2029 8.5.3 Russia mRNA Vaccines and Therapeutics: Market Forecast 2019-2029 8.5.4 South Africa mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
11. Conclusion 11.1 The World mRNA Vaccines and Therapeutics Market in 2018-2029 11.2 Current Leading mRNA Vaccines and Therapeutics Segments 11.3 Leading mRNA Vaccines and Therapeutics Companies 11.4 Leading Regional Markets
Appendices Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain Visiongain report evaluation form
List of Tables Table 4.1 Global mRNA Vaccines and Therapeutics Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 6.1 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 6.2 Global Standardized Therapeutic Cancer mRNA Vaccines Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029 Table 6.3 Global Individualized Therapeutic Cancer mRNA Vaccines Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029 Table 6.4 Global Therapeutic Infectious Disease mRNA Vaccines Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029 Table 6.5 Global mRNA Therapeutic for Other Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029 Table 7.1 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 7.2 Global Bioengineered Vaccine Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029 Table 7.3 Global Gene Therapy (Gene Silencing/Suppression) Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029 Table 7.4 Global Gene Transcription (Protein Generation) Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029 Table 7.5 Global Cell Therapy Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029 Table 7.6 Global Monoclonal Antibody Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029 Table 7.7 Global Other Mechanism of Actions Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029 Table 8.1 World mRNA Vaccines and Therapeutics Market by Region: Revenue ($bn) and Market Share (%) 2018 and 2029 Table 8.2 Global mRNA Vaccines and Therapeutics Market Forecast by Region: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.3 North America mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.4 North America mRNA Vaccines and Therapeutics Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.5 US mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029 Table 8.6 Canada mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.7 Europe mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.8 Europe mRNA Vaccines and Therapeutics Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.9 Germany mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.10 UK mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.11 French mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.12 Italian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.13 Spanish mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029 Table 8.14 Asia-Pacific mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.15 Asia-Pacific mRNA Vaccines and Therapeutics Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.16 Japanese mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.17 Chinese mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.18 Indian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029 Table 8.19 RoW mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.20 RoW mRNA Vaccines and Therapeutics Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.21 Brazilian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.22 Mexico mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.23 Russia mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 8.24 South Africa mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029 Table 9.1 Promising mRNA Vaccines and Therapies Pipeline Molecules Analysis, 2018 Table 9.2 Standardized mRNA Cancer Vaccines Pipeline Molecules Analysis, 2018 Table 9.3 Standardized mRNA Cancer Vaccines Pipeline Molecules Analysis, 2018 Table 9.4 Individualized mRNA Cancer Vaccines Pipeline Molecules Analysis, 2018 Table 9.5 Prophylactic mRNA Infectious Disease Vaccines Pipeline Molecules Analysis, 2018 Table 9.6 mRNA Protein Therapeutics for Ornithine TransCarbomylase Deficiency Pipeline Molecules Analysis, 2018 Table 9.7 mRNA Protein Therapeutics for Cancer and Cardiovascular Diseases Pipeline Molecules Analysis, 2018 Table 9.8 mRNA Protein Therapeutics for Cystic Fibrosis Pipeline Molecules Analysis, 2018 Table 9.9 mRNA Protein Therapeutics for Cystic Fibrosis Pipeline Molecules Analysis, 2018 Table 9.10 mRNA Protein Therapeutics for Cystic Fibrosis Pipeline Molecules Analysis, 2018 Table 9.11 mRNA Antibody Therapeutics Pipeline Molecules Analysis, 2018 Table 10.1 Overview: Moderna Therapeutics Table 10.2 Moderna Therapeutics: Product Portfolio Table 10.3 Recent Developments: Moderna Therapeutics Table 10.4 Overview: Sangamo Therapeutics Table 10.5 Sangamo Therapeutics: Product Portfolio Table 10.6 Recent Developments: Sangamo Therapeutics, Inc. Table 10.7 Overview: Argos Therapeutics Table 10.8 Argos Therapeutics: Product Portfolio Table 10.9 Recent Developments: Argos Therapeutics, Inc. Table 10.10 Overview: CureVac Table 10.11 CureVac: Product Portfolio Table 10.12 Recent Developments: CureVac AG Table 10.13 Overview: Translate Bio Table 10.14 Translate Bio: Product Portfolio Table 10.15 Recent Developments: Translate Bio Table 10.16 Overview: BioNTech Table 10.17 BioNTech: Product Portfolio Table 10.18 Recent Developments: BioNTech Table 10.19 Overview: In-Cell-Art Table 10.20 In-Cell-Art: Product Portfolio Table 10.21 Recent Developments: Translate Bio Table 10.22 Overview: eTheRNA Immunotherapies Table 10.23 eTheRNA Immunotherapies: Product Portfolio Table 10.24 Recent Developments: Translate Bio Table 10.25 Overview: Ethris GmbH Table 10.26 Ethris GmbH: Product Portfolio Table 10.27 Recent Developments: ethris GmbH Table 10.28 Overview: Tiba Biotech Table 10.29 Tiba Biotech: Product Portfolio
List of Figures Figure 4.1 Global mRNA Vaccines and Therapeutics Market Forecast Revenue ($bn), AGR (%) 2019-2029 Figure 4.2 Global mRNA Vaccines and Therapeutics Market Forecast Share (%) by Region 2019-2029 Figure 5.1 mRNA Vaccines and Therapeutics Market: Drivers and Restraints 2019-2029 Figure 6.1 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Revenue ($bn), 2019-2029 Figure 6.2 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Market Share (%), 2019-2029 Figure 6.3 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Market Shares (%), 2018 Figure 6.4 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Market Shares (%), 2024 Figure 6.5 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Market Shares (%), 2029 Figure 6.6 Global Standardized Therapeutic Cancer mRNA Vaccines Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 6.7 Global Individualized Therapeutic Cancer mRNA Vaccines Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 6.8 Global Therapeutic Infectious Disease mRNA Vaccines Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 6.9 Global mRNA Therapeutic for Other Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 7.1 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Revenue ($bn) 2019-2029 Figure 7.2 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Market Share (%) 2019-2029 Figure 7.3 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Market Shares (%), 2018 Figure 7.4 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Market Shares (%), 2024 Figure 7.5 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Market Shares (%), 2029 Figure 7.6 Global Bioengineered Vaccine Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 7.7 Global Gene Therapy (Gene Silencing/Suppression) Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 7.8 Global Gene Transcription (Protein Generation) Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 7.9 Global Cell Therapy Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 7.10 Global Monoclonal Antibody Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 7.11 Global Other Mechanism of Actions Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.1 Global mRNA Vaccines and Therapeutics Market by Region: Revenues (%), 2018 Figure 8.2 Global mRNA Vaccines and Therapeutics Market by Region: Revenues (%), 2024 Figure 8.3 Global mRNA Vaccines and Therapeutics Market by Region: Revenues (%), 2029 Figure 8.4 North America mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.5 North America mRNA Vaccines and Therapeutics Market Forecast by Region: Share (%) 2019-2029 Figure 8.6 US mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.7 Canada mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.8 Europe mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.9 Europe mRNA Vaccines and Therapeutics Market by Country: Share (%), 2019-2029 Figure 8.10 Germany mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2018-2029 Figure 8.11 UK mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.12 French mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.13 Italian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.14 Spanish mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2018-2029 Figure 8.15 Asia-Pacific mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.16 Asia-Pacific mRNA Vaccines and Therapeutics Market by Country: Share (%), 2019-2029 Figure 8.17 Japanese mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.18 Chinese mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.19 Indian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2018-2029 Figure 8.20 RoW mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.21 RoW mRNA Vaccines and Therapeutics Market by Country: Share (%), 2018-2029 Figure 8.22 Brazilian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.23 Mexico mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.24 Russia mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 8.25 South Africa mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029 Figure 10.1 Moderna Therapeutics: Financial Overview, 2016-2018 Figure 10.2 Sangamo Therapeutics: Financial Overview, 2016-2018 Figure 10.3 Argos Therapeutics: Financial Overview, 2016-2018 Figure 11.1 Global mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%) 2019-2029 Figure 11.2 Global mRNA Vaccines and Therapeutics Market Forecast by Country: Share (%) 2019-2029
Adaptive Biotechnologies Corporation Arcturus Therapeutics Ltd. Argos Therapeutics, Inc. AstraZeneca Bayer BioNet-Asia BioNTech AG BioNTech Diagnostics GmbH Bioverativ Inc. Brammer Bio Caperna LLC CELLSCRIPT, LLC CureVac AG Dow AgroSciences LLC Effimune Eli Lilly and Company Elpidera LLC eTheRNA immunotherapies NV ethris GmbH F. Hoffmann-La Roche Ltd. Genentech, Inc. Genevant Sciences In-Cell-Art Institut Pasteur Kite Pharma, Inc. MAB Discovery GmbH Merck & Co. Metropolis Healthcare Ltd. Moderna Therapeutics Mymetics BV Mymetics Corporation Okinawa Health Biotechnology Research and Development Center Open Monoclonal Technology, Inc. PCI Biotech Personalis, Inc. Pfizer Inc. Pharmaceutical Product Development, LLC (PPD) Sangamo Therapeutics, Inc. Sanofi Pasteur S.A. Shire International GmbH Shuwen Biotech Co. Ltd. Sigma-Aldrich Corporation Tiba Biotech LLC Translate Bio Translate Bio, Inc. TxCell, SA Valeant Pharmaceuticals International Inc. Valera LLC Vertex Pharmaceuticals Virbac
List of Organizations Mentioned in the Report American Cancer Society American Diabetes Organization Bill & Melinda Gates Foundation Biomedical Advanced Research and Development Authority (BARDA) Cancer Research UK Defense Advanced Research Projects Agency Friedrich-Loeffler-Institute Institute of Immunology of the Centre de Recherche Public-Santé (CRP) Karolinska Institutet Karolinska University Hospital (KUH) The Coalition for Epidemic Preparedness Innovations (CEPI) U.S. Food and Drug Administration (FDA) University of Pennsylvania (Penn) World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for mRNA Vaccines and Therapeutics Market Forecast 2019-2029
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report
The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.
“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report
Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.
“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report
Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.
